| Previous Close | 7.7 |
| Open | 7.65 |
| Day High | 7.73 |
| Day Low | 7.42 |
| 52-Week High | 13.02 |
| 52-Week Low | 6.13 |
| Volume | 1.05M |
| Average Volume | 1.06M |
| Market Cap | 582.11M |
| PE | 3.93 |
| EPS | 1.89 |
| Moving Average 50 Days | 7.88 |
| Moving Average 200 Days | 8.02 |
| Change | -0.28 |
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
GlobeNewswire Inc.
Mar 05, 2026 12:30 PM GMT
‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPP
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
GlobeNewswire Inc.
Mar 02, 2026 1:30 PM GMT
BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announce
CorMedix Therapeutics Announces Share Repurchase Program
GlobeNewswire Inc.
Feb 02, 2026 1:30 PM GMT
BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced